Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades

• Published in: Frontiers in oncology 2021-05, Vol.11, p.650122-650122
• Main Authors: Wang, Xiaoyan, Wu, Bingchen, Yan, Zhengqing, Wang, Guoqiang, Chen, Shiqing, Zeng, Jian, Tao, Feng, Xu, Bichun, Ke, Honggang, Li, Mei
• Format: Article
• Language: English
• Subjects: immune checkpoint blockades; JAK-STAT; non-small cell lung cancer; Oncology; PTPRD; PTPRT
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.650122

The common gamma receptor–dependent cytokines and their JAK-STAT pathways play important roles in T cell immunity and have been demonstrated to be related with response to immune checkpoint blockades (ICBs). PTPRD and PTPRT are phosphatases involved in JAK-STAT pathway. However, their clinical significance for non-small cell lung cancer (NSCLC) treated with ICBs is still unclear. Genomic and survival data of NSCLC patients administrated with anti–PD-1/PD-L1 or anti–CTLA-4 antibodies (Rizvi2015; Hellmann2018; Rizvi2018 Samstein2019) were retrieved from publicly accessible data. Genomic, survival and mRNA data of 1007 patients with NSCLC were obtained from The Cancer Genome Atlas (TCGA). PTPRD/PTPRT mutation was significantly associated with better progression-free survival (PFS) in three independent Rizvi2015, Hellmann2018 and Rizvi2018 cohorts. The median PFS for PTPRD/PTPRT mutant-type vs . wild-type NSCLC patients were not reached vs . 6.3 months (Rizvi2015, HR = 0.16; 95% CI, 0.02-1.17; P=0.03), 24.0 vs . 5.4 months (Hellmann2018, HR, 0.49; 95% CI, 0.26-0.94; P=0.03), 5.6 vs . 3.0 months (Rizvi2018, HR = 0.64; 95% CI, 0.44-0.92; P=0.01) and 6.8 vs . 3.5 months (Pooled cohort, HR, 0.54; 95% CI, 0.39-0.73; P